12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Deals

AstraZeneca, CRI, Ludwig Institute deal

The institutes will conduct clinical trials of cancer immunotherapy combinations, including three mAbs from AstraZeneca's MedImmune LLC biologics unit as well as other immunotherapies that have yet to be chosen. Funding will be provided by the Cancer Research...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >